@DKellyMD

[@DKellyMD @DeirdreKellyMD]

🚨Rejected twice. Now FDA accelerated approval.

RP1/Tudriqev + nivolumab for PD-1–refractory melanoma.

Single-arm; efficacy n=91
→ 24.2% responded; median duration 14.1 months
Promising. Shrinkage ≠ longer/better lives.

Can phase III confirm benefit? @OncoAlert #MELSM

[@DKellyMD @DeirdreKellyMD]

🚨A pill nearly doubled median survival in metastatic pancreatic cancer. FDA now reviewing it.

RASolute 302 | n=500 | 2L
Daraxonrasib vs chemo:
✅OS 13.2 vs 6.7 mo | HR 0.40

Not response rate. Not PFS alone. Overall survival.

@EileenMOReilly @OncoAlert
https://t.co/Y2GmtjZhim

[@DKellyMD @DeirdreKellyMD]

🚨 Blood test. 50+ cancers. FDA panel 23 Sept.
NHS-Galleri | 143k

❌Stage III/IV endpoint missed
✅14% fewer stage IV cancers overall; 26% fewer in round 3*
❓Survival benefit unknown

Enough to screen millions?

*Secondary endpoint
@OncoAlert
https://t.co/57fRkm4DwI

[@DKellyMD @DeirdreKellyMD]

🎯 In oncogene-driven NSCLC, finding the target is only step 1.

ALK/ROS1/RET:
➡️Which TKI first?
➡️How to preserve CNS control?
➡️When to repeat profiling?
➡️How to treat resistance?
Timely #DCLung26 with Dr Natasha Leighl.
@MedStarHealth @IASLC #LCSM

[Stephen V Liu, MD @StephenVLiu]

Join us in Washington, DC on Saturday, October 10 for #DCLung26 - a one-day, comprehensive, multidisciplinary, discussion-based lung cancer CME update! Come learn from Dr. Natasha Leighl about treating NSCLC with ALK, ROS1, and RET fusions!

https://t.co/EGGHrShgD7

[Stephen V Liu, MD @StephenVLiu]

In this latest episode of the @IASLC podcast, Lung Cancer Considered, I discuss the latest FDA approval for lung cancer: zidesamtinib for advanced ROS1 NSCLC with Drs. @alexdrilon and @charocampelo. How does this shake up the landscape? Listen now!

https://t.co/qgqn6ghDnI

[@DKellyMD @DeirdreKellyMD]

🚨 SCLC ADCs are moving beyond DLL3

Iza-bren delivers topo-I via EGFR+HER3:

➡️ORR 48% (n=52)
➡️2nd-line: 73% response | PFS 6.2m | OS 15m (n=22)
⚠️No control; median response 4.9m

❓Signal—or phase-I selection?
@JCO_ASCO @OncoAlert #LCSM
https://t.co/AGXWHPbTzx

[@DKellyMD @DeirdreKellyMD]

🚨 COMPASS | Beyond PD-L1/TMB?

➡️AI models tumour immunity—not one marker
➡️1,133 pts/7 cancers/6 ICIs
➡️Beat 22 models
➡️Maps potential resistance pathways

Promise: smarter trials + combos
⚠️Not clinic-ready
👏@WanXiang_Shen @marinkazitnik @OncoAlert
https://t.co/Burddwr1tV

[@DKellyMD @DeirdreKellyMD]

🏃CHALLENGE | post-adjuvant CRC

➡️DFS HR 0.72
➡️8y OS 90.3% vs 83.2%
➡️5y Canadian payer: −CAD$1,589; +0.10 QALYs

If a drug did this, uptake would be urgent.

❓Should Ireland fund this as cancer treatment?
👏🏻@vic_coyle @GillSharlene @CDNCancerTrials
https://t.co/oy8z29ZiGT

[@DKellyMD @DeirdreKellyMD]

🚨 Ph3 ELEVATE | adjuvant ensartinib
Resected II–IIIB ALK+ NSCLC

➡️2y DFS 86.4% vs 53.5% placebo
➡️HR 0.20 (95% CI 0.11–0.38)
➡️OS immature

🧬 Test early
👏🏻 Strong DFS signal
❓How to position post-ALINA?

@NEJM @ALKPositiveinc @OncoAlert #LCSM
https://t.co/gN0f4I9mcv

[@DKellyMD @DeirdreKellyMD]

25 yrs @MaterCancer CTRU!

150+ trials | 1.5k+ pts
13/24 @hseNCCP cancer drugs since ’11 tested here
30+ trials published
Ph II–III➡️@STARTDublin Ph I

Future➡️biomarkers,adaptive design,⬆️accrual

@UCD_Research @IrishCancerSoc @CancerTrialsIE @HSELive @OECI_EEIG @myESMO @CCRT

[Ana I. Velázquez Mañana, MD, MSc, FASCO @AnaVManana]

So what is the recommended supportive care for patients starting amivantamab + lazertinib?
🔹 PO steroids to ⬇️ infusion reaction (days -2, -1, 0)
🔹 anticoagulation for VTE prophylaxis (first 4 mo)
🔹 oral doxycycline (wks 1-12)
🔹 clindamycin to scalp (wks 13+)
🔹 4% chlorhexidine to nails
🔹 ceramide-based moisturizer
🔹 Importantly (and not in the slide) can't forget the Sunscreen ☀️

Complex supportive care that requires working closely with our nursing teams to ensure adequate patient education and comfort.

#ELCC25 #ELCC2025 #LCSM #LungCancer @nicogirardcurie #COCOON

[@DKellyMD @DeirdreKellyMD]

#ELCC2025
@ZPiotrowskaMD 1L EGFRm+ NSCLC

osim+chemo (FLAURA2) & amiv+lazertinib (MARIPOSA) ⬆️PFS vs osi alone—early tox

↑ CNS mets, high burden, ctDNA+ may need intensification
Low-risk pts may do well on TKI alone

Nuanced decisions ahead
@DanaFarber @OncoAlert @IASLC

[@DKellyMD @DeirdreKellyMD]

#ELCC2025 Unresectable III EGFRm NSCLC
@DrSanjayPopat

PACIFIC: durva not effective in EGFRm
LAURA: osimertinib ↑ PFS (HR 0.24–0.23, PET±), pneumonitis ↑
POLESTAR: similar benefit w/ aumolertinib
Is upfront TKI next? (NeoADAURA in pipeline)
@IASLC @OncoAlert @LCRF_org

[@DKellyMD @DeirdreKellyMD]

ESCLC Genomics
JulieGeorge #ELCC2025

TP53 & RB1 loss = near-universal
chr3/11 chromothripsis = rare, recurrent
Inflamed subtype → ↑ chemo-IO response
MYC amp, NOTCH mut, DLL3↑ = NE phenotype
Clonal neoAgs = vaccine potential

@IASLC @OncoAlert @ETOP_IBCSG @NatureRevClinOnc

[@DKellyMD @DeirdreKellyMD]

Thymic Tumors #ELCC2025 @nicogirardcurie
Heterogeneous dz➡️MDT essential

Stage IV? Still surgical candidates
Induction chemo → >50% R0
Chemo+IO: 56% RR (❌not in thymoma – risk irAEs)
CGP:target in 1/3(CKIT~10%)
Guidelines & dedicated boards needed

@ITMIG1 @RareCancersEU

[@DKellyMD @DeirdreKellyMD]

#ELCC2025 @AlixPanabieres
Liquid bx = dynamic real-time insight into tumour biology
Captures ctDNA, CTCs, exosomes, immune + microbial signals
High-value for MRD, monitoring, prognosis
Context critical
Functional biomarker ≠ tissue gold standard.
@myESMO @OncoAlert #LCSM

[@DKellyMD @DeirdreKellyMD]

@MartinReck2 #ELCC25
New ICI targets: TIGIT, LAG-3, TIM-3, NKG2A, CD73
CCR8 & B7-H3 (Ph1/2)
Trials in periop & consolidative settings
Backbone = anti–PD-1/PD-L1 ± anti–CTLA-4
Tissue-rich trials needed to map individual immunosuppressive drivers
#LCSM @IASLC @OncoAlert @myESMO

[@DKellyMD @DeirdreKellyMD]

Opening Ceremony #ELCC25 ��
Prof. Keith Kerr receives Heine H. Hansen Award 👏
SCLC-4 molecular subtypes
Co-mutations ⬆️dx
ADCs - IHC quantification essential
AI can assess post-Rx tissue infer mutations
Pathologists central to ⬆️lung ca outcomes
#ELCC25 #LCSM

[@DKellyMD @DeirdreKellyMD]

#ELCC2025 @peters_solange on 10y of IO
stable Incidence ⬇️mortality➡️IO contributing
SOC: stop IO @ 2y if CR; benefit >2y ➡️ unclear
Oligomets: MDT can consider local Rx
Subcut IO :⬆️pt preference ⬇️time/cost, enables decentralised Tx
@OncoAlert @ThoracicOnc #LCSM @myESMO

[@DKellyMD @DeirdreKellyMD]

#ELCC2025 #OlafMercier on early-stage NSCLC @peters_solange discuss-broaden periop IO?
🔹15–20% don’t reach surgery in neoadj trials
🔹Resectable upfront is key
🔁 1y post-op IO ⇒ ↑DFS
🔬#ADOPTlung explores adj IO
@IASLC @myESMO #LCSM @OncoAlert @ThoracicOnc @BTOGORG @EORTC